256 related articles for article (PubMed ID: 23796284)
21. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
Romero I; Mallol P; Santaballa A; Del Campo JM; Mori M; González-Santiago S; Casado A; Vicente D; Ortega E; Herrero A; Guerra E; Barretina-Ginesta P; Rubio MJ; Martínez A; Bover I; Vidal L; Arcusa Á; Martín L; García Y; González-Martín A
Anticancer Drugs; 2019 Jul; 30(6):628-635. PubMed ID: 31008727
[TBL] [Abstract][Full Text] [Related]
22. The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Giuliani J; Bonetti A
Int J Gynecol Cancer; 2017 Nov; 27(9):1872-1876. PubMed ID: 28976446
[TBL] [Abstract][Full Text] [Related]
23. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
Pignata S; Scambia G; Villanucci A; Naglieri E; Ibarbia MA; Brusa F; Bourgeois H; Sorio R; Casado A; Reichert D; Dopchie C; De Rivas B; de Sande LM
Oncologist; 2021 Apr; 26(4):e658-e668. PubMed ID: 33289956
[TBL] [Abstract][Full Text] [Related]
24. GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
Selle F; Heudel PE; Hardy-Bessard AC; Pozet A; Meunier J; Gladieff L; Lotz JP; Provansal M; Augereau P; Berton D; Bonichon-Lamichhane N; Orfeuvre H; Pautier P; Kalbacher E; Tazi Y; Spaeth D
Anticancer Res; 2020 Jul; 40(7):3939-3945. PubMed ID: 32620635
[TBL] [Abstract][Full Text] [Related]
25. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
26. Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey.
Ferrandina G; Amadio G; Paris I; Distefano M; Palluzzi E; de Vincenzo R; Ricci C; Scambia G
Int J Gynecol Cancer; 2017 Jul; 27(6):1141-1148. PubMed ID: 28574933
[TBL] [Abstract][Full Text] [Related]
27. Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.
Del Campo JM; Muñoz-Couselo E; Diaz de Corcuera I; Oaknin A
Expert Rev Anticancer Ther; 2010 Jun; 10(6):795-805. PubMed ID: 20553205
[TBL] [Abstract][Full Text] [Related]
28. Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line.
Colombo N
Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):13-17. PubMed ID: 30223694
[TBL] [Abstract][Full Text] [Related]
29. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA
J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448
[TBL] [Abstract][Full Text] [Related]
30. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
[TBL] [Abstract][Full Text] [Related]
31. Trabectedin plus pegylated liposomal doxorubicin: the return of a treatment option for ovarian cancer.
Clare J
Future Oncol; 2013 Dec; 9(12 Suppl):1. PubMed ID: 24195522
[No Abstract] [Full Text] [Related]
32. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
Pignata S; Scambia G; Ferrandina G; Savarese A; Sorio R; Breda E; Gebbia V; Musso P; Frigerio L; Del Medico P; Lombardi AV; Febbraro A; Scollo P; Ferro A; Tamberi S; Brandes A; Ravaioli A; Valerio MR; Aitini E; Natale D; Scaltriti L; Greggi S; Pisano C; Lorusso D; Salutari V; Legge F; Di Maio M; Morabito A; Gallo C; Perrone F
J Clin Oncol; 2011 Sep; 29(27):3628-35. PubMed ID: 21844495
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of trabectedin in treating ovarian cancer.
Teplinsky E; Herzog TJ
Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
[TBL] [Abstract][Full Text] [Related]
34. Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.
Monk BJ; Kaye SB; Poveda A; Herzog TJ; Aracil M; Nieto A; Badri N; Parekh TV; Tanović A; Galmarini CM
Gynecol Oncol; 2014 Jan; 132(1):176-80. PubMed ID: 24211400
[TBL] [Abstract][Full Text] [Related]
35. Treatment of recurrent ovarian cancer.
Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
[TBL] [Abstract][Full Text] [Related]
37. Increasing the chances for platinum-sensitive ovarian cancer patients.
González A
Future Oncol; 2013 Dec; 9(12 Suppl):29-35. PubMed ID: 24195528
[TBL] [Abstract][Full Text] [Related]
38. Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience.
Dear RF; Gao B; Harnett P
Asia Pac J Clin Oncol; 2010 Mar; 6(1):66-73. PubMed ID: 20398040
[TBL] [Abstract][Full Text] [Related]
39. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.
Rakowski JA; Ahmad S; Holloway RW
Expert Rev Anticancer Ther; 2012 Jan; 12(1):31-40. PubMed ID: 22149430
[TBL] [Abstract][Full Text] [Related]
40. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]